Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds

A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found. The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who…#carvykti #lenalidomide #oreofeodejide #drbinoddhakal #milwaukee
Source: Reuters: Health - Category: Consumer Health News Source Type: news